Breaking News Instant updates and real-time market news.

2022-05-19 08:07:44 CLBS Caladrius / + 08:07 05/19/22 05/19 08:07 05/19/22 08:07	Caladrius: IDMC recommends continuation of CLBS201 trial without modification Caladrius Biosciences announced that the Independent Data Monitoring Committee overseeing the Phase 1b, open-label, proof-of-concept study of CLBS201 for the treatment of diabetic kidney disease has reviewed the initial safety and tolerability data from the first two, sequentially treated, patients. Based on their assessment of the data, the IDMC approved proceeding with the enrollment of the remaining four patients in the study without further review. "We are very pleased with the progress of the study and with the recommendations of the IDMC," stated Kristen K. Buck, M.D., Executive Vice President of R&D and Chief Medical Officer of Caladrius. "We find it encouraging that CLBS201 appeared to be well-tolerated based on the initial assessment of data. We look forward to continuing this study and hope to rapidly enroll the remaining patients, leading to top-line data by the first quarter of 2023."

2022-05-19 08:07:44

CLBS

Caladrius

/ +

08:07

05/19/22

05/19

08:07

05/19/22

08:07

Caladrius: IDMC recommends continuation of CLBS201 trial without modification

Caladrius Biosciences announced that the Independent Data Monitoring Committee overseeing the Phase 1b, open-label, proof-of-concept study of CLBS201 for the treatment of diabetic kidney disease has reviewed the initial safety and tolerability data from the first two, sequentially treated, patients. Based on their assessment of the data, the IDMC approved proceeding with the enrollment of the remaining four patients in the study without further review. "We are very pleased with the progress of the study and with the recommendations of the IDMC," stated Kristen K. Buck, M.D., Executive Vice President of R&D and Chief Medical Officer of Caladrius. "We find it encouraging that CLBS201 appeared to be well-tolerated based on the initial assessment of data. We look forward to continuing this study and hope to rapidly enroll the remaining patients, leading to top-line data by the first quarter of 2023."

OTHER BREAKING NEWS FROM THE FLY

Downgrade	Provident Financial downgraded to Hold from Add at Peel Hunt » 04:54 02/03/23 02/03 04:54 02/03/23 04:54 FPLPF Provident Financial $1.98 / + (+0.00%) Peel Hunt analyst Robert… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research FPLPF Provident Financial $1.98 / + (+0.00%) 10/20/22 Barclays Provident Financial price target lowered to 310 GBp from 370 GBp at Barclays 10/19/22 Keefe Bruyette Provident downgraded to Underperform from Market Perform at Keefe Bruyette
Downgrade	Merck KGaA downgraded to Sell from Buy at DZ Bank » 04:53 02/03/23 02/03 04:53 02/03/23 04:53 MKGAY Merck KGaA $38.36 / + (+0.00%) DZ Bank analyst Peter… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research MKGAY Merck KGaA $38.36 / + (+0.00%) 12/22/22 Mersana reports research collaboration, commercial license pact with Merck KGaA MKGAY Merck KGaA $38.36 / + (+0.00%) 02/02/23 Citi Merck KGaA downgraded to Neutral from Buy at Citi 01/06/23 Morgan Stanley Merck KGaA upgraded to Overweight from Equal Weight at Morgan Stanley 12/14/22 UBS Merck KGaA upgraded to Buy from Neutral at UBS 11/14/22 BofA Merck KGaA upgraded to Buy from Neutral at BofA
Downgrade	Mercialys downgraded to Neutral from Outperform at Oddo BHF » 04:53 02/03/23 02/03 04:53 02/03/23 04:53 MEIYF Mercialys $10.70 / + (+0.00%) Oddo BHF analyst Florent… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research MEIYF Mercialys $10.70 / + (+0.00%) 02/03/22 Goldman Sachs Mercialys downgraded to Neutral from Buy at Goldman Sachs
Downgrade	Kinnevik downgraded to Sell from Hold at Nordea » 04:52 02/03/23 02/03 04:52 02/03/23 04:52 KNKBF Kinnevik $18.30 / +4.8 (+35.56%) Nordea analyst David… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research KNKBF Kinnevik $18.30 / +4.8 (+35.56%) 12/02/22 DNB Markets Kinnevik downgraded to Sell from Hold at DNB Markets 10/20/22 Nordea Kinnevik upgraded to Hold from Sell at Nordea 04/26/22 Deutsche Bank Kinnevik price target lowered to SEK 220 from SEK 290 at Deutsche Bank 04/22/22 Danske Bank Kinnevik upgraded to Hold from Sell at Danske Bank
Downgrade	KGHM Polska downgraded to Underweight from Equal Weight at Morgan Stanley » 04:52 02/03/23 02/03 04:52 02/03/23 04:52 KGHPF KGHM Polska $32.80 / + (+0.00%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research KGHPF KGHM Polska $32.80 / + (+0.00%) 01/26/23 JPMorgan KGHM Polska price target lowered to PLN 120 from PLN 125 at JPMorgan 12/14/22 JPMorgan KGHM Polska price target raised to PLN 125 from PLN 100 at JPMorgan 11/21/22 JPMorgan KGHM Polska price target lowered to PLN 100 from PLN 115 at JPMorgan 11/15/22 Erste Group KGHM Polska downgraded to Hold from Buy at Erste Group
Downgrade	IWG downgraded to Equal Weight from Overweight at Barclays » 04:50 02/03/23 02/03 04:50 02/03/23 04:50 IWGFF IWG $2.41 / +0.09 (+3.88%) Barclays analyst James… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research IWGFF IWG $2.41 / +0.09 (+3.88%) 11/02/22 Barclays IWG price target lowered to 190 GBp from 230 GBp at Barclays 08/10/22 Barclays IWG price target lowered to 230 GBp from 300 GBp at Barclays 08/10/22 Peel Hunt IWG downgraded to Add from Buy at Peel Hunt 05/10/22 Berenberg IWG upgraded to Buy from Hold at Berenberg
Downgrade	Electrolux downgraded to Hold from Buy at SEB Equities » 04:49 02/03/23 02/03 04:49 02/03/23 04:49 ELUXY Electrolux $25.90 / -2.89 (-10.04%) SEB Equities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research ELUXY Electrolux $25.90 / -2.89 (-10.04%) 09/02/22 Electrolux to exit Russia, divests business to local management ELUXY Electrolux $25.90 / -2.89 (-10.04%) 11/30/22 Exane BNP Paribas Electrolux upgraded to Outperform from Neutral at Exane BNP Paribas 10/31/22 JPMorgan Electrolux price target raised to SEK 116 from SEK 115 at JPMorgan 10/03/22 JPMorgan Electrolux price target lowered to SEK 115 from SEK 120 at JPMorgan 09/20/22 JPMorgan Electrolux price target lowered to SEK 120 from SEK 135 at JPMorgan
Downgrade	Bakkavor Group downgraded to Reduce from Hold at HSBC » 04:48 02/03/23 02/03 04:48 02/03/23 04:48 BKKVF Bakkavor Group $1.73 / + (+0.00%) HSBC analyst Doriana… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research BKKVF Bakkavor Group $1.73 / + (+0.00%) 11/18/22 HSBC Bakkavor downgraded to Hold on cost pressures at HSBC 11/18/22 HSBC Bakkavor Group downgraded to Hold from Buy at HSBC 05/27/22 Berenberg Bakkavor Group price target lowered to 110 GBp from 125 GBp at Berenberg 03/22/22 Berenberg Bakkavor Group price target lowered to 125 GBp from 145 GBp at Berenberg
Downgrade	Alfa Laval downgraded to Hold from Buy at DNB Markets » 04:47 02/03/23 02/03 04:47 02/03/23 04:47 ALFVY Alfa Laval $34.44 / +2.265 (+7.04%) DNB Markets analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research ALFVY Alfa Laval $34.44 / +2.265 (+7.04%) 08/31/22 Alfa Laval acquires Scanjet ALFVY Alfa Laval $34.44 / +2.265 (+7.04%) 01/24/23 Nordea Alfa Laval downgraded to Hold from Buy at Nordea 12/08/22 JPMorgan Alfa Laval price target lowered to SEK 265 from SEK 270 at JPMorgan 12/08/22 Credit Suisse Alfa Laval price target raised to SEK 275 from SEK 265 at Credit Suisse 12/08/22 Deutsche Bank Alfa Laval initiated with a Hold at Deutsche Bank
Upgrade	Pirelli upgraded to Overweight from Equal Weight at Morgan Stanley » 04:46 02/03/23 02/03 04:46 02/03/23 04:46 PLLIF Pirelli $5.45 / + (+0.00%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research PLLIF Pirelli $5.45 / + (+0.00%) 01/10/23 Deutsche Bank Pirelli upgraded to Buy from Hold at Deutsche Bank 04/05/22 Citi Pirelli upgraded to Buy from Neutral at Citi 02/16/22 Citi Pirelli price target raised to EUR 6.30 from EUR 5.80 at Citi

Downgrade	SSAB AB downgraded to Equal Weight from Overweight at Morgan Stanley » 04:44 02/03/23 02/03 04:44 02/03/23 04:44 SSAAY SSAB AB $3.51 / + (+0.00%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research On The Fly SSAAY SSAB AB $3.51 / + (+0.00%) 02/02/23 Kepler Cheuvreux SSAB AB downgraded to Hold from Buy at Kepler Cheuvreux 02/01/23 Barclays SSAB AB price target raised to SEK 72 from SEK 65 at Barclays 01/30/23 Deutsche Bank SSAB AB price target raised to SEK 71 from SEK 68 at Deutsche Bank 01/30/23 JPMorgan SSAB AB price target raised to SEK 59 from SEK 55 at JPMorgan SSAAY SSAB AB $3.51 / + (+0.00%) 12/22/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Downgrade	Friedrich Vorwerk downgraded to Hold from Buy at Berenberg » 04:43 02/03/23 02/03 04:43 02/03/23 04:43 FRVWY Friedrich Vorwerk $3.50 / -0.25 (-6.67%) Berenberg analyst Lasse… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research FRVWY Friedrich Vorwerk $3.50 / -0.25 (-6.67%) 01/31/23 Jefferies Vorwerk Group SE downgraded to Hold from Buy at Jefferies
Downgrade	Asos downgraded to Hold from Buy at Deutsche Bank » 04:40 02/03/23 02/03 04:40 02/03/23 04:40 ASOMY Asos $12.01 / +0.83 (+7.42%) Deutsche Bank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research ASOMY Asos $12.01 / +0.83 (+7.42%) 02/01/23 HSBC Asos upgraded to Hold from Reduce at HSBC 01/24/23 Morgan Stanley Asos price target raised to 730 GBp from 660 GBp at Morgan Stanley 01/13/23 JPMorgan Asos price target lowered to 1,000 GBp from 1,170 GBp at JPMorgan 01/13/23 Societe Generale Asos price target raised to 1,180 GBp from 1,072 GBp at Societe Generale
Downgrade	Pets at Home Group downgraded to Hold from Buy at Deutsche Bank » 04:39 02/03/23 02/03 04:39 02/03/23 04:39 PAHGF Pets at Home Group $3.42 / + (+0.00%) Deutsche Bank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research PAHGF Pets at Home Group $3.42 / + (+0.00%) 02/02/23 Liberum Pets at Home Group downgraded to Hold from Buy at Liberum 11/03/22 Berenberg Pets at Home Group price target lowered to 370 GBp from 470 GBp at Berenberg 08/09/22 Jefferies Pets at Home Group initiated with a Buy at Jefferies 07/04/22 RBC Capital Pets at Home Group downgraded to Underperform from Sector Perform at RBC Capital
Downgrade	Kingfisher downgraded to Hold from Buy at Deutsche Bank » 04:39 02/03/23 02/03 04:39 02/03/23 04:39 KGFHY Kingfisher $7.17 / +0.26 (+3.76%) Deutsche Bank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research KGFHY Kingfisher $7.17 / +0.26 (+3.76%) 12/02/22 Deutsche Bank Kingfisher price target lowered to 275 GBp from 280 GBp at Deutsche Bank 11/17/22 JPMorgan Kingfisher price target lowered to 210 GBp from 220 GBp at JPMorgan 11/07/22 Credit Suisse Kingfisher downgraded to Neutral from Outperform at Credit Suisse 09/27/22 Deutsche Bank Kingfisher price target raised to 280 GBp from 270 GBp at Deutsche Bank
Upgrade	Inditex upgraded to Hold from Sell at Deutsche Bank » 04:38 02/03/23 02/03 04:38 02/03/23 04:38 IDEXY Inditex $15.76 / -0.19 (-1.19%) Deutsche Bank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research IDEXY Inditex $15.76 / -0.19 (-1.19%) 12/16/22 Societe Generale Inditex downgraded to Hold from Buy at Societe Generale 12/15/22 Deutsche Bank Inditex price target raised to EUR 23 from EUR 22.50 at Deutsche Bank 12/02/22 Morgan Stanley Inditex assumed with an Equal Weight at Morgan Stanley 09/15/22 Credit Suisse Inditex price target raised to EUR 21.50 from EUR 20.50 at Credit Suisse
Upgrade	B&M European Value Retail upgraded to Buy from Hold at Deutsche Bank » 04:37 02/03/23 02/03 04:37 02/03/23 04:37 BMRRY B&M European Value Retail $23.34 / +0.85 (+3.78%) Deutsche Bank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research BMRRY B&M European Value Retail $23.34 / +0.85 (+3.78%) 01/06/23 JPMorgan B&M European Value price target lowered to EUR 540 from EUR 555 at JPMorgan 01/06/23 Barclays B&M European Value price target raised to 485 GBp from 475 GBp at Barclays 01/06/23 Deutsche Bank B&M European Value price target raised to 460 GBp from 415 GBp at Deutsche Bank 12/30/22 Credit Suisse Credit Suisse sees some U.K. retailers increasing guidance
Upgrade	Marks & Spencer upgraded to Buy from Hold at Deutsche Bank » 04:37 02/03/23 02/03 04:37 02/03/23 04:37 MAKSY Marks & Spencer $4.00 / +0.19 (+4.99%) Deutsche Bank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research MAKSY Marks & Spencer $4.00 / +0.19 (+4.99%) 09/30/22 Linde completes sale of Gist to Marks & Spencer MAKSY Marks & Spencer $4.00 / +0.19 (+4.99%) 01/13/23 Barclays Marks & Spencer price target raised to 165 GBp from 155 GBp at Barclays 01/13/23 JPMorgan Marks & Spencer price target raised to 115 GBp from 100 GBp at JPMorgan 01/13/23 Citi Marks & Spencer price target raised to 150 GBp from 125 GBp at Citi 12/30/22 Credit Suisse Credit Suisse sees some U.K. retailers increasing guidance
Upgrade	Standard Chartered upgraded to Buy from Hold at Investec » 04:34 02/03/23 02/03 04:34 02/03/23 04:34 SCBFF Standard Chartered $8.15 / + (+0.00%) Investec analyst Ian… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research SCBFF Standard Chartered $8.15 / + (+0.00%) 02/01/23 Goldman Sachs Standard Chartered downgraded to Neutral from Buy at Goldman Sachs 01/16/23 Deutsche Bank Standard Chartered downgraded to Hold from Buy at Deutsche Bank 01/06/23 Investec Standard Chartered downgraded to Hold from Buy at Investec 12/06/22 JPMorgan Standard Chartered price target raised to 800 GBp from 770 GBp at JPMorgan
Recommendations	Amazon.com price target raised to $123 from $119 at Piper Sandler » 04:32 02/03/23 02/03 04:32 02/03/23 04:32 AMZN Amazon.com $112.65 / +7.48 (+7.11%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options AMZN Amazon.com $112.65 / +7.48 (+7.11%) 02/02/23 Amazon says YTD AWS revenue growth in mid-teens y/y so far 02/02/23 Amazon saw continued efficiencies in transportation network in Q4 02/02/23 Amazon down 5% ahead of Q4 earnings call 02/02/23 Amazon down fractionally after Q4 report, Q1 guidance AMZN Amazon.com $112.65 / +7.48 (+7.11%) 02/02/23 Morgan Stanley Meta Platforms price target raised to $190 from $130 at Morgan Stanley 02/01/23 Oppenheimer Oppenheimer says channel checks support below-consensus AWS estimates 02/01/23 Morgan Stanley Buy with Prime could be $3.5B-plus EBIT business for Amazon, says Morgan Stanley 01/30/23 UBS Amazon's Buy with Prime puts up to 14% of Shopify revenue at risk, says UBS AMZN Amazon.com $112.65 / +7.48 (+7.11%) 02/02/23 Amazon sees Q1 revenue $121B-$126B, consensus $125.11B 02/02/23 Amazon reports Q4 EPS 3c with Rivian loss, consensus 17c 02/02/23 Notable companies reporting after market close 10/27/22 Amazon sees Q4 revenue $140B-$148B, consensus $155.15B AMZN Amazon.com $112.65 / +7.48 (+7.11%) 02/02/23 Beyond Meat revamps retail sales strategy around five grocers, WSJ says 02/01/23 Judge rules Amazon supervisors broke law in anti-union efforts, NYTimes reports 02/01/23 Amazon's layoffs hit robotics, grocery, health, AWS units, CNBC reports 01/29/23 Amazon raises price minimum for free grocery delivery, WSJ reports AMZN Amazon.com $112.65 / +7.48 (+7.11%) 02/02/23 Fly Intel: After-Hours Movers 02/02/23 What Wall Street is saying about Alphabet ahead of earnings 02/01/23 Here's what Wall Street is saying about Amazon ahead of earnings 01/30/23 Fly Intel: Pre-market Movers 02/13/23 Technology/Finance AMZN Amazon.com $112.65 / +7.48 (+7.11%) 02/02/23 Amazon options imply 7.0% move in share price post-earnings 02/02/23 Notable open interest changes for February 2nd 01/31/23 Notable open interest changes for January 31st 01/30/23 Notable open interest changes for January 30th

Recommendations	Alphabet price target lowered to $120 from $122 at Piper Sandler » 04:30 02/03/23 02/03 04:30 02/03/23 04:30 GOOGL Alphabet $107.71 / +7.275 (+7.24%) , GOOG Alphabet $108.77 / +7.375 (+7.27%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options GOOGL GOOG GOOGL Alphabet $107.71 / +7.275 (+7.24%) 02/02/23 Alphabet says started bringing revenue sharing to YouTube Shorts 02/02/23 Alphabet reports Q4 Google Cloud revenue $7.3B vs. $5.54B last year 02/02/23 Alphabet taking actions to optimize global office space 02/01/23 'Tomb Raider Reloaded' coming to Google Play, iOS, Netflix on February 14 GOOG Alphabet $108.77 / +7.375 (+7.27%) 02/02/23 Alphabet says started bringing revenue sharing to YouTube Shorts 02/02/23 Alphabet reports Q4 Google Cloud revenue $7.3B vs. $5.54B last year 02/02/23 Alphabet taking actions to optimize global office space 02/01/23 'Tomb Raider Reloaded' coming to Google Play, iOS, Netflix on February 14 GOOGL GOOG GOOGL Alphabet $107.71 / +7.275 (+7.24%) 02/02/23 Morgan Stanley Meta Platforms price target raised to $190 from $130 at Morgan Stanley 01/31/23 BofA Alphabet price target raised to $119 at BofA ahead of earnings 01/30/23 KeyBanc Trade Desk price target lowered to $55 from $56 at KeyBanc 01/30/23 KeyBanc Alphabet price target lowered to $117 from $118 at KeyBanc GOOG Alphabet $108.77 / +7.375 (+7.27%) 02/02/23 Morgan Stanley Meta Platforms price target raised to $190 from $130 at Morgan Stanley 01/31/23 BofA Alphabet price target raised to $119 at BofA ahead of earnings 01/30/23 KeyBanc Trade Desk price target lowered to $55 from $56 at KeyBanc 01/30/23 KeyBanc Alphabet price target lowered to $117 from $118 at KeyBanc GOOGL GOOG GOOGL Alphabet $107.71 / +7.275 (+7.24%) 02/02/23 Alphabet reports Q4 EPS $1.05, consensus $1.18 02/02/23 Notable companies reporting after market close 10/25/22 Alphabet reports Q3 EPS $1.06, consensus $1.25 10/25/22 Notable companies reporting after market close GOOG Alphabet $108.77 / +7.375 (+7.27%) 02/02/23 Alphabet reports Q4 EPS $1.05, consensus $1.18 02/02/23 Notable companies reporting after market close 10/25/22 Alphabet reports Q3 EPS $1.06, consensus $1.25 10/25/22 Notable companies reporting after market close GOOGL GOOG GOOGL Alphabet $107.71 / +7.275 (+7.24%) 02/02/23 Democratic senator joins calls to ban TikTok, WSJ reports 02/01/23 GoodRx to pay $1.5M fine over sharing health data, Bloomberg Law reports 02/01/23 Google testing ChatGPT-like products, including 'Apprentice Bard,' CNBC reports 01/31/23 Reels sharing revenue with creators hotly debated within Meta, Information says GOOG Alphabet $108.77 / +7.375 (+7.27%) 02/02/23 Democratic senator joins calls to ban TikTok, WSJ reports 02/01/23 GoodRx to pay $1.5M fine over sharing health data, Bloomberg Law reports 02/01/23 Google testing ChatGPT-like products, including 'Apprentice Bard,' CNBC reports 01/31/23 Reels sharing revenue with creators hotly debated within Meta, Information says GOOGL GOOG GOOGL Alphabet $107.71 / +7.275 (+7.24%) 02/02/23 Fly Intel: After-Hours Movers 02/02/23 What You Missed On Wall Street On Thursday 02/02/23 What You Missed On Wall Street This Morning 02/02/23 What Wall Street is saying about Alphabet ahead of earnings GOOG Alphabet $108.77 / +7.375 (+7.27%) 02/02/23 What You Missed On Wall Street On Thursday 02/02/23 What You Missed On Wall Street This Morning 02/02/23 What Wall Street is saying about Alphabet ahead of earnings 02/01/23 #SocialStocks: Meta circumvents FTC challenge and will acquire Within Unlimited GOOGL GOOG GOOGL Alphabet $107.71 / +7.275 (+7.24%) 02/02/23 Alphabet Class A options imply 5.4% move in share price post-earnings 02/02/23 Early notable gainers among liquid option names on February 2nd 01/20/23 Early notable gainers among liquid option names on January 20th 01/20/23 Unusually active option classes on open January 20th GOOG Alphabet $108.77 / +7.375 (+7.27%) 02/02/23 Alphabet options imply 5.9% move in share price post-earnings 01/20/23 Unusually active option classes on open January 20th 12/14/22 Alphabet put buyer realizes 126% same-day gains 11/02/22 Alphabet put buyer realizes 98% same-day gains
Recommendations	Gilead price target raised to $112 from $111 at Piper Sandler » 04:28 02/03/23 02/03 04:28 02/03/23 04:28 GILD Gilead $81.37 / -2.625 (-3.13%) Piper Sandler analyst Do… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options GILD Gilead $81.37 / -2.625 (-3.13%) 02/02/23 Gilead raises quarterly dividend 2.7% to 75c per share 01/30/23 Kite and Arcellx close pact to develop late-stage clinical CART-ddBCMA in MM 01/04/23 Hookipa Pharma achieves $5M milestone payment from Gilead 01/03/23 EVOQ to potentially receive $658.5M in Gilead collaboration on immunotherapies GILD Gilead $81.37 / -2.625 (-3.13%) 01/30/23 Truist Truist sees potential pressure on Seagen's Padcev in Q4 01/19/23 Piper Sandler Gilead price target raised to $111 from $104 at Piper Sandler 01/03/23 RBC Capital RBC downgrades Gilead, says drivers need time to play out 01/03/23 RBC Capital Gilead downgraded to Sector Perform from Outperform at RBC Capital GILD Gilead $81.37 / -2.625 (-3.13%) 02/02/23 Gilead sees FY23 adjusted EPS $6.60-$7.00, consensus $6.73 02/02/23 Gilead reports Q4 adjusted EPS $1.67, consensus $1.49 02/02/23 Notable companies reporting after market close 12/20/22 Gilead expects Tmunity acquisition to reduce FY23 EPS by 18c-22c GILD Gilead $81.37 / -2.625 (-3.13%) 02/02/23 Fly Intel: After-Hours Movers 12/30/22 What You Missed On Wall Street This Morning 12/30/22 Biotech Alert: Searches spiking for these stocks today 12/28/22 What You Missed On Wall Street On Wednesday 02/16/23 2023 Tandem Meetings of ASTCG and CIBMTR 02/12/23 PDUFA Date for TRODELVY 02/07/23 Gilead 02/08/23 Gilead GILD Gilead $81.37 / -2.625 (-3.13%) 02/02/23 Gilead options imply 3.5% move in share price post-earnings 11/02/22 Unusually active option classes on open November 2nd 10/28/22 Early notable gainers among liquid option names on October 28th 10/27/22 Gilead options imply 2.6% move in share price post-earnings
Recommendations	Conmed price target raised to $118 from $108 at Piper Sandler » 04:27 02/03/23 02/03 04:27 02/03/23 04:27 CNMD Conmed $107.27 / +8.02 (+8.08%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events CNMD Conmed $107.27 / +8.02 (+8.08%) 02/02/23 Conmed: Results impacted by implementation of warehouse management system CNMD Conmed $107.27 / +8.02 (+8.08%) 02/02/23 Piper Sandler Conmed price target raised to $118 from $108 at Piper Sandler 10/26/22 Piper Sandler Conmed price target lowered to $108 from $118 at Piper Sandler 10/26/22 Piper Sandler Piper Sandler keeps Neutral on Integra after results, favors Conmed and Tandem 10/14/22 Needham Conmed price target lowered to $90 from $123 at Needham CNMD Conmed $107.27 / +8.02 (+8.08%) 02/02/23 Conmed sees FY23 adjusted EPS $3.20-$3.45, consensus $3.37 02/02/23 Conmed reports Q4 EPS 86c, consensus 90c 11/15/22 Conmed sees FY23 EPS $3.20-$3.50 , consensus $3.39 11/15/22 Conmed withdraws previously issued FY22 guidance CNMD Conmed $107.27 / +8.02 (+8.08%) 02/02/23 Fly Intel: After-Hours Movers 10/26/22 Fly Intel: After-Hours Movers 03/08/23 Piper Sandler Hosted Company Meetings at AAOS 2023 Annual Meeting
Initiation	Privia Health initiated with a Buy at Goldman Sachs » 04:26 02/03/23 02/03 04:26 02/03/23 04:26 PRVA Privia Health $27.62 / +0.05 (+0.18%) Goldman Sachs analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events PRVA Privia Health $27.62 / +0.05 (+0.18%) 01/17/23 Privia Health announces launches of ACOs in Delaware and North Carolina 12/05/22 NeoGenomics names Jeffrey Sherman as new CFO 11/15/22 Privia Health announces Butler resigned from board of directors 10/03/22 Director of Privia Health sold 80,853 shares of company stock PRVA Privia Health $27.62 / +0.05 (+0.18%) 01/17/23 Piper Sandler Piper Sandler would be a buyer of Privia Health following CMS data 01/09/23 BTIG Privia Health price target lowered to $40 from $45 at BTIG 12/08/22 Stifel Privia Health initiated with a Buy at Stifel 12/08/22 UBS Privia Health initiated with a Buy at UBS PRVA Privia Health $27.62 / +0.05 (+0.18%) 11/10/22 Privia Health raises FY22 revenue view to $1.3B-$1.335B from $1.225B-$1.3B 11/10/22 Privia Health reports Q3 adjusted EPS 13c, consensus 0c 08/11/22 Privia Health sees 2022 revenue at high end of $1.225B-$1.3B 08/11/22 Privia Health reports Q2 adjusted EPS 13c vs. 9c last year. 17 Nov PRVA Privia Health $27.62 / +0.05 (+0.18%) 11/15/22 Fly Intel: After-Hours Movers 02/28/23 Privia Health - PRVA
Initiation	Agios Pharmaceuticals initiated with an Overweight at Piper Sandler » 04:25 02/03/23 02/03 04:25 02/03/23 04:25 AGIO Agios Pharmaceuticals $30.16 / +0.74 (+2.52%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events AGIO Agios Pharmaceuticals $30.16 / +0.74 (+2.52%) 12/11/22 Agios Pharmaceuticals presents updated PYRUKYND long-term extension data 12/11/22 Agios Pharmaceuticals presents updated PYRUKYND data 12/06/22 Agios Pharmaceuticals appoints Tsveta Milanova as CCO 11/03/22 Agios Pharmaceuticals expects cash to fund operations through catalysts AGIO Agios Pharmaceuticals $30.16 / +0.74 (+2.52%) 11/17/22 Goldman Sachs Agios Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs 07/27/22 SVB Securities Agios Pharmaceuticals upgraded to Outperform from Market Perform at SVB Securities 02/25/22 RBC Capital Agios Pharmaceuticals price target raised to $67 from $61 at RBC Capital 02/24/22 H.C. Wainwright Agios Pharmaceuticals price target lowered to $96 from $98 at H.C. Wainwright AGIO Agios Pharmaceuticals $30.16 / +0.74 (+2.52%) 11/03/22 Agios Pharmaceuticals reports Q3 EPS ($1.49), consensus ($1.76) 08/04/22 Agios Pharmaceuticals reports Q2 EPS ($1.68), consensus ($1.75) AGIO Agios Pharmaceuticals $30.16 / +0.74 (+2.52%) 11/21/22 Biotech Alert: Searches spiking for these stocks today 02/23/23 Agios Pharmaceuticals - AGIO

Events

Earnings calls, analyst events, roadshows and more

AVTR
Today at 08:00

Avantor - AVTR Conference Calls
TWST
Today at 08:00

Twist Bioscience - TWST Conference Calls
SNY
Today at 08:00

Sanofi - SNY Conference Calls
Today at 08:30

Employment Situation: Average Workweek: January 2023 Government Event
Today at 08:30

Employment Situation: Private Payrolls M/M: January 2023 Government Event
Today at 08:30

Employment Situation: Manufacturing Payrolls M/M: January 2023 Government Event
Today at 08:30

Employment Situation: Participation Rate: January 2023 Government Event
Today at 08:30

Employment Situation: Average Hourly Earnings M/M: January 2023 Government Event
Today at 08:30

Employment Situation: Non-Farm Payrolls M/M: January 2023 Government Event
Today at 08:30

Employment Situation: Average Hourly Earnings Y/Y: January 2023 Government Event

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	No deals
Wed	VERA X VERA Vera Therapeutics Spot Secondary Managers: JPMorgan, Cowen & Evercore ISI, LIFC Priced at: $7.00 14.286M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	ALGM X ALGM Allegro MicroSystems Block Trade Managers: Credit Suisse Priced at: $38.00 4.98M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial GPCR X GPCR Structure Therapeutics IPO Managers: Jefferies, SVB Securities, Guggenheim & BMO Capital Priced at: $15.00 10.74M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ROIV X ROIV Roivant Sciences Secondary Managers: Goldman Sachs, SVB Securities, Cowen & Cantor Fitzgerald Priced at: $7.50 26.67M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AVTX X AVTX Avalo Therapeutics Spot Secondary Managers: SVB Securities & RBC Capital Priced at: $3.98 3.77M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EDBL X EDBL Edible Garden Spot Secondary Managers: Maxim & Joseph Gunnar Priced at: $6.30 1.62M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	No deals
Wed	WULF X WULF TeraWulf Spot Secondary Managers: JonesResearch $1.03
Thurs	ASST X ASST Asset Entities IPO Managers: Boustead $5.00 1.5M Shares SODR X SODR Sondors IPO Managers: DA Davidson & Lake Street $8.00 - 10.00 2.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MDXH X MDXH MDxHealth Secondary Managers: Cowen & William Blair, BTIG, KBCS $6.75 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CLLS X CLLS Cellectis Spot Secondary Managers: Jefferies & Barclays $3.26 22M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TWO X TWO Two Harbors Spot Secondary Managers: Goldman Sachs, JPMorgan & Citi, JMP Securities $17.80-18.00 10M Shares
Fri	No deals

View All Syndicate Announcements »

Caladrius: IDMC recommends continuation of CLBS201 trial without modification

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access